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ABSTRACT
Objectives The main objective of this study was to 
determine whether the dna methylation profile of 
children born to mothers with rheumatoid arthritis (Ra) is 
different from that of children born to mothers from the 
general population. in addition, we aimed to determine 
whether any differences in methylation are associated 
with maternal Ra disease activity or medication use 
during pregnancy.
Methods For this study, genome-wide dna 
methylation was measured at cytosine-phosphate-
guanine (cpg) sites, using the infinium illumina 
Humanmethylation 450K Beadchip, in 80 blood samples 
from children (mean age=6.8 years) born to mothers 
with Ra. as controls, blood samples from 354 children 
(mean age=6.0 years) from the population-based 
generation R study were used. linear mixed models 
were performed to investigate differential methylation 
between the groups, corrected for relevant confounders.
Results a total of 147 cpgs were differentially 
methylated between blood samples of children born 
to mothers with Ra and the control blood samples. 
The five most significantly associated cpgs were 
cg06642177, cg08867893, cg06778273, cg07786668 
and cg20116574. The differences in methylation were 
not associated with maternal Ra disease activity or 
medication use during pregnancy.
Conclusions dna methylation at 147 cpgs differed 
between children born to mothers with Ra and children 
born to mothers from the general population. it remains 
unknown whether the identified associations are causal, 
and if so whether they are caused by the disease or 
treatment. more research, including replication of these 
results, is necessary in order to strengthen the relevance 
of our findings for the later-life health of children born to 
mothers with Ra.
Adverse exposures in early life are associated with 
later-life health, which is referred to as the devel-
opmental origins of health and disease hypoth-
esis.1–5 Epigenetic processes are thought to be 
one of the mechanisms underlying the associa-
tions of early-life exposures and later-life health 
outcomes.6 7 DNA methylation is the best studied 
and understood epigenetic modification.8 9 Factors 
that have been demonstrated to be associated with 
fetal DNA methylation include maternal disease,7 
malnutrition,10–13 smoking,14 placental insuffi-
ciency,15 corticosteroids,16 folate depletion17 and 
cytokines.18 DNA methylation usually occurs at 
cytosine-phosphate-guanine (CpG) sites.8 9 The 
effect of hypermethylation and hypomethylation on 
gene expression depends on the CpG location.19 20 
The most pronounced changes in DNA methylation 
occur during early pregnancy.7 11
During embryogenesis, there are three germ 
layers that form in the developing fetus (ectoderm, 
mesoderm and endoderm). When DNA methyla-
tion is altered in early pregnancy, all germ layers 
are affected.21 22
Rheumatoid arthritis (RA) may be considered as 
an adverse exposure during pregnancy.23 Therefore, 
it is plausible that maternal RA may induce changes 
in fetal DNA methylation, and that it is related 
with the later-life health of the offspring. Inter-
leukin-6 is known to influence DNA methylation.18 
RA treatment during pregnancy includes among 
others sulfasalazine (SSZ) and corticosteroids 
such as prednisone. SSZ is a known folate antag-
onist that crosses the placenta and could influence 
DNA methylation in this respect.17 24 Furthermore, 
corticosteroids might influence DNA methyla-
tion.16 Especially during early pregnancy, when the 
placenta is not completely developed, prednisone 
passively diffuses to the fetus.25–28
In the current study we investigated whether 
the DNA methylation profile of children born to 
mothers with RA was different from that of chil-
dren born to mothers from the general popula-
tion. Furthermore, we investigated whether any 
differentially methylated CpGs were associated 
Key messages
What is already known about this subject?
 ► Adverse exposures in early life are associated 
with later-life health.
 ► Epigenetic changes are thought to be one of the 
underlying mechanisms.
 ► There is not much known about the 
consequences of maternal rheumatoid arthritis 
(RA) on the offsprings’ long-term health.
What does this study add?
 ► DNA methylation is different in children born to 
mothers with RA compared with mothers from 
the general population.
How might this impact on clinical practice or 
future developments?
 ► Maternal RA disease during pregnancy might 
have lifelong consequences for the offspring.
 ► More research in this particular field must be 
undertaken.
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with RA disease activity or medication use during pregnancy, or 
with indicators of future metabolic and cardiovascular diseases. 
In addition, we examined whether these CpGs were associated 
with the expression of genes using expression quantitative trait 
methylation (eQTM) analysis.
MeTHOdS
Study population
FEPRA study
This study is embedded in the Pregnancy-induced Amelioration 
of Rheumatoid Arthritis (PARA) study, a prospective cohort 
study on pregnancy and RA.29 From 2002 to 2008, 369 female 
patients with RA who had a wish to conceive (or already preg-
nant) were enrolled.30 31 After participation in the PARA study, 
196 children and their parents were invited to participate 
in a follow-up study, the FEtal Programming in Rheumatoid 
Arthritis (FEPRA) study. For this study, 108 children with a 
mean age of 6.8 years (SD=1.3) visited Erasmus Medical Centre 
in Rotterdam, and the parents of 85 children (all of European 
ancestry) gave informed consent for studies on DNA methyla-
tion of their children. Furthermore, the parents of 71 children 
provided cheek swabs from their children. There were no statis-
tical differences in baseline characteristics between the partici-
pating and non-participating group.
Generation R Study
The control group consisted of children with a mean age of 6.0 
years (SD=0.4), included in the Generation R Study, a popula-
tion-based prospective cohort study from pregnancy onwards in 
Rotterdam, the Netherlands.32 In this study, all pregnant women 
living in Rotterdam with a delivery date between April 2002 and 
January 2006 were invited to participate, and 9778 mothers 
were enrolled.32 At the age of 6 years, DNA methylation was 
measured in a subgroup of 493 children of European ancestry.
data collection
FEPRA study
In the PARA study, data on mother (eg, disease activity (with 
the Disease Activity Score in 28 joints using C reactive protein 
levels, DAS28-CRP3)) and child were collected.31 For the FEPRA 
study, data on blood pressure, growth and body composition of 
the children were measured. Also, blood, which is a mesoderm 
germ layer derivate, was drawn for DNA methylation analysis.33 
Cheek swabs were collected for the analysis of DNA methyla-
tion in buccal epithelial cells, which is an ectoderm germ layer 
derivate.
Generation R Study
In the Generation R Study, mothers were seen three times during 
pregnancy. The children were followed from birth until child-
hood. Data collection in children and their mothers included 
questionnaires, detailed physical examinations and blood 
sampling.32
dNA methylation analysis
Genomic DNA was extracted from whole peripheral blood 
samples and from the cheek swab samples. Bisulfite conversion of 
500 ng of genomic DNA was performed using the Zymo EZ-96 
DNA Methylation Kit (Zymo Research, Irvine, California, USA) 
according to the manufacturer’s protocol.
Genomic methylation profiling was performed using the 
Infinium Illumina HumanMethylation 450K BeadChip arrays 
(Illumina, San Diego, USA) according to the manufacturer’s 
protocol. The Illumina array measures methylation status of 485 
512 CpG sites in the gene and non-gene regions across the entire 
human genome. To prevent possible batch effects, blood and 
cheek swab samples were measured in the same run.
Quality control and normalisation
The data were preprocessed using the minfi package in R V.3.4.1 
( www. r- project. org). Samples with incomplete or poor bisul-
fite conversion, extension, hybridisation or specificity were 
excluded.34 In addition, samples with sex mismatch and samples 
with a call rate <95% were removed. This quality control (QC) 
was done separately for blood samples and for cheek swab 
samples. During QC, 5 blood and 14 cheek swab samples from 
the FEPRA study were excluded, resulting in 80 and 57 samples, 
respectively. From the Generation R blood samples, 27 were 
excluded due to corticosteroid use or RA disease in the mother, 
and 32 were excluded during QC, resulting in 441 blood samples. 
In addition, 87 cases with missing data from the Generation R 
Study were excluded, leaving 354 samples to analyse. The inten-
sity values were then quantile normalised using the incorporating 
Control Probe Adjustment and reduction of global CORrelation 
(CPACOR) workflow.34 Methylation at each CpG was calculated 
as the beta value (beta=intensity of the methylated allele (M)/
(intensity of the unmethylated allele (U)+M+100)), containing 
values from 0 to 1. Blood cell composition of the samples was 
estimated using the Houseman method with the Reinius refer-
ence set.35 36 The Reinius reference set is not yet validated in 
children. However, it is the best method available, and it has 
been used in other epigenetic studies in children.37 38 Probes with 
single nucleotide polymorphisms (SNPs) at single base exten-
sion, probes with improper binding, and CpGs on the X and 
Y chromosome were removed from the analysis.37–40 From the 
initial 485 512 CpGs, 32 057 were excluded during QC, leaving 
453 456 CpGs for analysis.
Statistical analysis
For all subjects, descriptive statistics were calculated using Stata 
V.14.1 (https://www. stata. com/ stata14/). Student’s t-tests and χ2 
tests were used to compare the baseline characteristics. For these 
analyses, p values <0.05 were considered statistically significant.
Linear mixed models were performed to analyse differential 
methylation between the groups, using R. The first model was 
created to compare the blood samples from the FEPRA study 
with the blood samples of the Generation R Study to deter-
mine whether the DNA methylation profile of children born to 
mothers with RA was different from that of children born to 
mothers from the general population. This model was corrected 
for biological covariates (age, body mass index (BMI) SD scores 
(SDS), adjusted for age and sex according to the Dutch refer-
ence values, using the Growth Analyser (V.4.0; Growth Analyser, 
Rotterdam, the Netherlands, www. growthanalyser. org,) sex, 
gestational age at delivery, maternal age, folic acid use during 
pregnancy, socioeconomic status (SES), maternal smoking and 
white blood cell subtypes), technical covariates (technical batch 
effects (array identifier (ID) and position on array)) and five 
hidden confounders. Technical covariates were added as random 
effects in the models. The hidden confounders were calculated 
using the CATE package41 42 while correcting for the group (RA 
vs non-RA offsprings), all biological covariates and technical 
covariates. This resulted in hidden confounders that were inde-
pendent of all included covariates. The BACON package42 was 
used to correct for unobserved covariates in order to reduce 
test statistic bias and inflation. The genomic inflation factor 
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Figure 1 Flow chart of the study population and exclusion of 
participants. FEPRA, FEtal Programming in Rheumatoid Arthritis; RA, 
rheumatoid arthritis.
Table 1 Descriptive statistics of study population
FePRA study 
(n=80)
Generation R 
Study (n=354)
Age child* (years), mean (SD) 6.8 (1.3)† 6.0 (0.4)†
BMI SDS child,* mean (SD) −0.14 (0.87)† 0.18 (0.74)†
Sex of the child
  Male, n (%) 46 (57.5) 176 (49.7)
  Female, n (%) 34 (42.5) 178 (50.3)
Maternal age at delivery (years), mean 
(SD)
32.9 (3.9) 32.5 (4.0)
Gestational age (weeks), mean (SD) 39.5 (2.0)† 40.2 (1.5)†
Gestational age <37 weeks, n (%) 8 (10.0)† 6 (1.7)†
Folic acid
  Start before pregnancy, n (%) 25 (31.3)† 212 (59.9)†
  Start in early pregnancy, n (%) 19 (23.8)† 116 (32.8)†
  No use, n (%) 36 (45.0)† 26 (7.3)†
SES based on educational level
  Low, n (%) 9 (11.3)† 4 (1.1)†
  Middle, n (%) 33 (41.3)† 108 (30.5)†
  High, n (%) 38 (47.5)† 242 (68.4)†
  Maternal smoking,‡ n (%) 1 (1.3)† 86 (24.3)†
  DAS28-CRP(3) third trimester, mean 
(SD)
3.3 (1.1) –
Use of medication ≥1 trimester
  Only prednisone use, n (%) 17 (21.3) –
  Only sulfasalazine use, n (%) 14 (17.5) –
  Combination, n (%) 13 (16.3) –
Prednisone dose (mg), median (IQR)
  First trimester 7.5 (2.5–10.0) –
  Second trimester 7.5 (5.0–10.0) –
  Third trimester 6.3 (5.0–10.0) –
No medication use, n (%) 36 (45.0) –
Fat percentage SDS, mean (SD) 0.24 (0.97) –
*At time of the blood sampling.
†P<0.001.
‡During pregnancy.
BMI, body mass index; DAS28-CRP(3), Disease Activity Score in 28 joints using C 
reactive protein levels; FEPRA, FEtal Programming in Rheumatoid Arthritis; SDS, SD 
score; SES, socioeconomic status.
(λ)43 was calculated. After QC, 453 456 CpGs remained for 
analysis. Therefore, a Bonferroni-adjusted p value of 0.05/453 
456=1.10×10−7 was used.44
CpGs were annotated for nearby genes with the Genomic 
Regions Enrichment of Annotations Tool,45 a general method 
to present epigenetic data.37 38 40 Significant CpGs from the first 
analysis were then further analysed within the blood samples of 
the FEPRA study to explore if RA disease activity, prednisone 
use or SSZ use during pregnancy would explain the differences 
in methylation found in the first model. After that, two linear 
mixed models were created with the significant CpGs to iden-
tify whether these were associated with the BMI SDS or the fat 
percentage SDS of the child, as indicators of future metabolic 
disease. These models were analysed in the 80 blood samples of 
the FEPRA study. CpGs with a p value below 0.05/147=3.4×10−4 
were considered statistically significant.
The significant CpGs found in the first analysis were also 
analysed in DNA derived from buccal epithelial cells, obtained 
by cheek swabs from the FEPRA study, to explore if the differ-
entially methylated CpGs were also differentially methylated in 
that germ layer derivate, as a kind of validation of the results. 
For this analysis, CpGs with a p value below significance level of 
3.4×10−4 were considered statistically significant.
eQTM analysis
eQTMs are sites at which DNA methylation is known to influ-
ence the expression of one or more genes.46 To analyse whether 
any of the significant CpGs were linked to the expression of 
nearby genes, an eQTM analysis was performed. For these anal-
yses the online BIOS QTL browser (https:// molgenis26. target. 
rug. nl/ downloads/ biosqtlbrowser/) was used.39
ReSulTS
Participants
The flow chart of the study population is shown in figure 1. A 
total of 80 blood and 57 cheek swab samples from the FEPRA 
study (children born to mothers with RA) and 354 blood samples 
from the Generation R Study (children born to mothers from the 
general population) remained for analysis.
Descriptive statistics of the study population are presented in 
table 1. Overall, children from the FEPRA study were slightly 
older compared with children in the Generation R Study 
(p<0.001). In the FEPRA study, 45% of the women did not start using folic acid before or in early pregnancy compared with 
92.7% in the Generation R Study (p<0.001). Approximately 
half of the women (47.5%) from the FEPRA study had a high 
SES compared with 68.4% of the women from the Generation 
R Study (p<0.001). One woman (1.3%) from the FEPRA study 
and 86 women (24.3%) from the Generation R Study smoked 
periconceptionally or at any time during pregnancy (p<0.001).
dNA methylation analysis
In the first linear mixed model, blood samples from the FEPRA 
study were compared with blood samples from the Generation 
R Study, corrected for the covariates mentioned in the Methods 
section. In total, 147 CpGs were significantly differentially 
methylated between children in the FEPRA study and children 
in the Generation R Study (figure 2). The QQ plot is shown in 
figure 3. The genomic inflation factor (λ) was 1.06.
In table 2 the five most significant CpGs and the five CpGs 
with the largest effect sizes (within the significant CpGs) are 
described in detail. The complete list of significantly associated 
CpGs is provided as an online supplementary file. A positive 
beta represents higher methylation levels in children born to 
mothers with RA. Methylation was higher in children born to 
4300.7802.430. Protected by copyright.
 o
n
 N
ovem
ber 28, 2019 at Erasm
us M
edical / X51
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214930 on 29 M
ay 2019. Downloaded from
 
1201Ince-Askan H, et al. Ann Rheum Dis 2019;78:1198–1204. doi:10.1136/annrheumdis-2018-214930
Rheumatoid arthritis
Figure 2 Results of the analysis of DNA methylation in children born 
to mother with rheumatoid arthritis (FEPRA study) compared with 
children born to women from the general population (Generation R 
Study). The chromosomes are depicted on the x-axis, and the −log p 
value on the y-axis. The red line represents the Bonferroni threshold 
for a significance of p=1.10×10−7. FEPRA, FEtal Programming in 
Rheumatoid Arthritis.
Figure 3 QQ plot of observed versus expected p values from 
the analysis of DNA methylation in children born to mother with 
rheumatoid arthritis (FEPRA study) compared with children born to 
women from the general population (Generation R Study). FEPRA, FEtal 
Programming in Rheumatoid Arthritis.
mothers with RA than in those from the general population at 
all five CpGs with the lowest p values. Methylation at the five 
CpGs with the largest effect sizes was lower in children born to 
mothers with RA, with the exception of cg06656994.
Subsequent analysis of dNA methylation
The mean DAS28-CRP(3) in the first, second and third trimes-
ters (3.6, 3.5 and 3.3, respectively) were highly correlated 
(>0.6). The DAS28-CRP(3) in the third trimester was avail-
able in all patients. Therefore, this timepoint was chosen for 
the analysis. None of the 147 CpGs were significantly associ-
ated with maternal RA disease activity (DAS28-CRP(3)) in the 
third trimester or medication (prednisone or SSZ) use. In addi-
tion, none of the CpGs were associated with BMI SDS or fat 
percentage SDS in the children.
Analysis in buccal epithelial cells
A total of 10 out of the 147 CpGs significantly associated with 
maternal RA in blood were also associated in buccal epithelial 
cells. From these, four were in the same direction as in blood 
(table 3). CpG cg11336323 was located in a promoter region.
eQTM analysis
Two CpGs, cg21384971 and cg11220663, were associated 
with expression of the COPZ2 and ADD2 genes, respectively 
(table 4). These two genes were also the nearest genes to those 
CpGs.45 Both CpGs were hypermethylated in the children born 
to mothers with RA and were associated with decreased expres-
sion of COPZ2 and ADD2 in the BIOS eQTM lookup browser.
diSCuSSiON
This is the first study investigating the differences in DNA meth-
ylation of children born to mothers with RA compared with 
children born to mothers from the general population. In this 
unique study, all participants were followed prospectively from 
pregnancy onwards. Our study showed differential DNA meth-
ylation between the two groups. The differentially methylated 
CpG sites were not associated with disease activity and/or medi-
cation use, nor to BMI SDS and fat percentage SDS.
In total, 147 CpGs were significantly associated with maternal 
RA after adjustment for multiple biological and technical covari-
ates and hidden confounders. Of the five most significant 
CpGs, interestingly, two (cg06642177 and cg07786668) have 
been associated with myocardial infarction.47 The most signif-
icant CpG, cg06642177, is located on chromosome 6 near the 
SLC2A12 gene,48 associated with insulin sensitivity,48 49 heart 
failure and diabetes50 in animal models. cg07786668, located on 
chromosome 16, is located in the ZFHX3 gene. ZFHX3 has been 
associated in multiple human studies with atrial fibrillation,51–55 
coronary heart disease56 and obesity in a Korean population.57 
cg20116574 was annotated to the NCOA5, a protein coding 
gene, which has been associated with diabetes mellitus type 2 in 
animal models.58 59
From the remaining 142 CpGs, 1 (cg17218495), annotated 
to the SMARCA4 gene, has independently and significantly been 
associated with myocardial infarction.47 The other significant 
CpGs from our study have not been associated with disease 
phenotypes.
Out of the initial 147 significant CpGs, 10 were also signifi-
cantly differentially methylated in buccal epithelial cells obtained 
by cheek swabs. From these, four were in the same direction as 
in blood. When DNA methylation is altered in more than one 
germ layer derivate, it is likely that these alterations occurred in 
early development.21 22 These four CpGs have not been associ-
ated with disease phenotypes in humans. Unfortunately, in the 
Generation R Study, DNA methylation in buccal epithelial cells 
was not available. There were no publicly available epigenetic 
data sets on buccal epithelial cells in healthy children with a 
similar age and background.
As mentioned before, CpGs that are associated with eQTMs 
can influence the expression levels of genes.46 In our study, from 
the 147 significant CpGs, 2 were present in the BIOS QTL 
browser. cg21384971 is associated with less expression of the 
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Table 2 The five most significant CpGs (white rows) and the five CpGs with the largest effect size (grey rows) from the linear mixed model: DNA 
methylation in blood samples from children born to mothers with RA (FEPRA study) compared with children born to mothers from the general 
population (Generation R Study)
CpG Beta* Se P value Nearest gene (±bp) Chr bp location†
cg06642177 0.028 0.002 1.32×10−24 SLC2A12 (−122 529) 6 134 496 341 –
cg08867893 0.018 0.002 7.66×10−24 ZNF365 (+221) 10 64 134 160 –
cg06778273 0.024 0.002 3.77×10−23 TNFRSF18 (+4995) 1 1 137 117 –
cg07786668 0.026 0.002 7.11×10−23 ZFHX3 (−10 142) 16 73 092 391 –
cg20116574 0.019 0.002 5.91×10−19 NCOA5 (+435) 20 44 718 168 Promoter
cg16930947 −0.050 0.008 3.22×10−11 – 8 88 984 447 –
cg01485645 −0.044 0.006 1.64×10−13 MLLT6 (+303) 17 36 862 199 Promoter
cg12360123 −0.043 0.008 1.61×10−08 – 10 79 984 532 Enhancer
cg06656994 0.038 0.005 9.67×10−13 FAM163A (+903) 1 179 713 176 Enhancer
cg17483482 −0.037 0.006 4.62×10−10 – 1 117 152 162 –
*Beta represents the difference in DNA methylation at the given CpG site in children born to mothers with RA (FEPRA study) as compared with children born to mothers from 
the general population (Generation R Study).
†Location in promoter, enhancer or unknown (–).
bp, base pair; Chr, chromosome; CpG, cytosine-phosphate-guanine; FEPRA, FEtal Programming in Rheumatoid Arthritis; RA, rheumatoid arthritis.
Table 3 CpGs that were differentially methylated in the same direction in both blood and in buccal epithelial cells
CpG Beta* Se P value
Nearest gene 
(±bp) Chr bp location†
cg22998206 0.1029 0.022 4.40×10−06 – 12 49 239 429 –
cg03654106 0.0727 0.016 9.50×10−06 – 19 49 539 527 –
cg02613964 −0.058 0.014 7.57×10−05 – 3 44 690 321 –
cg11336323 −0.092 0.024 1.63×10−04 – 19 41 946 040 Promoter
*Beta represents the difference in DNA methylation at the given CpG site in buccal epithelial cells from children born to mothers with RA (FEPRA study) as compared with blood 
samples from children born to mothers from the general population (Generation R Study).
†Location in promoter, gene, enhancer or unknown (–).
bp, base pair; Chr, chromosome; CpG, cytosine-phosphate-guanine; FEPRA, FEtal Programming in Rheumatoid Arthritis; RA, rheumatoid arthritis.
COPZ2 gene, which has been studied as a therapeutic oppor-
tunity for proliferation-independent selective killing of tumour 
cells.60 cg11220663 is associated with less expression of the 
ADD2 gene, also known as beta-adducin. ADD2 is involved in 
multiple pathogenic processes with a wide range of diseases.61 
ADD2 gene variants are associated with hypertension,62 cancer61 
and systemic lupus erythematosus.63
Pathway analysis of the genes annotated to the 147 signifi-
cant CpGs, using the WebGestalt (WEB-based Gene Set AnaL-
ysis Toolkit),64 did not result in significant pathways (data not 
shown).
Thus, some of the associated CpGs (cg06642177, cg07786668 
and cg17218495) have been associated with cardiovascular 
disease in previous studies, while others are located in or near 
genes that are associated with cardiovascular or metabolic 
disease. Maternal RA during pregnancy, a chronic inflammatory 
disease, might be associated with later-life health and disease risk 
in the offspring.
None of the significant CpGs were associated with RA disease 
activity or medication use during pregnancy. However, this may 
have been due to a lack of power, since these analyses were 
performed in the 80 samples of the children born to women with 
RA. The same power problem also applied to the analysis of the 
CpGs with indicators for future metabolic and cardiovascular 
disease (BMI SDS and fat percentage).
Remarkably, a large percentage of women with RA did not use 
folic acid before or during pregnancy. Even though this is outside 
the scope of our study, this requires additional attention during 
preconceptional counselling.
Our study has some limitations. First, although in its kind it is 
a large study, a study on DNA methylation including 80 subjects 
and 354 controls is still relatively small. Despite this, a large 
number of CpGs reached significance. Correcting for biological 
and technical covariates, as well as hidden confounders, and 
using BACON resulted in a λ near 1, reflecting that there was 
no inflation. Second, we were not able to collect a new indepen-
dent cohort of children born to mothers with RA to replicate 
the results. At the time our study was performed, there were no 
other comparable prospective studies available. Currently, Euro-
pean research groups are conducting new prospective cohort 
studies on the impact of RA on pregnancy and offspring. We 
encourage these research groups, possibly with international 
collaborations, to replicate our study.
Thus, the results of this study may support follow-up research 
of children born to mothers with RA. Based on our data, we 
recommend that at least indicators for future cardiovascular 
and metabolic disease should be considered. The effects of RA 
disease activity and medication use on DNA methylation should 
be investigated in studies with larger sample sizes. Furthermore, 
in the last years the use of tumour necrosis factor (TNF) inhib-
itors during pregnancy in patients with RA has increased. This 
often results in lower RA disease activity during pregnancy. 
Future research should also cover the effects of the use of TNF 
inhibitors on the differentially methylated CpGs in children 
born to mothers with RA.
In addition, it would be interesting for a future study to measure 
DNA methylation in the mothers of the children from our study 
and compare that with the methylation of their offspring. Since 
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Table 4 Results from the eQTM analysis using the 147 CpGs significantly different in children born to mothers with RA (FEPRA study)
CpG Beta* Se* P value* Nearest genes Beta GN† Se GN† P value GN†
Genes 
GN†
cg21384971 0.029 0.004 3.86×10−13 COPZ2 −0.073 0.039 1.79×10−06 COPZ2
cg11220663 0.023 0.003 1.68×10−11 ADD2 −0.121 0.039 3.32×10−06 ADD2
The positive betas in column ‘Beta’ represent hypermethylation, while the negative betas in column ‘Beta GN’ represent decreased gene expression.
*The columns beta, SE, p value and nearest genes represent the results from the analysis of DNA methylation in children born to mothers with RA (FEPRA study) as compared 
with children born to mothers from the general population (Generation R Study).
†The columns beta GN, SE GN, p value GN and genes GN represent the results from the BIOS eQTM lookup browser.
CpG, cytosine-phosphate-guanine; eQTM, expression quantitative trait methylation; FEPRA, FEtal Programming in Rheumatoid Arthritis; GN, GeneNetwork; RA, rheumatoid 
arthritis.
mothers and children live in a shared environment (generally), 
there may be an overlap in differentially methylated CpGs.
In conclusion, maternal RA during pregnancy is associated 
with differential DNA methylation in offspring. It remains 
unknown whether the identified associations are causal, and if 
so whether they are caused by the disease or treatment. Some of 
the differentially methylated CpGs or their nearby genes were 
associated with cardiovascular or metabolic disease. Maternal 
RA disease might have lifelong consequences for the offspring. 
However, more research in this particular field must be under-
taken in order to strengthen the relevance of our findings.
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